Only Two Ring Sulfurs In The Hetero Ring Patents (Class 514/440)
  • Patent number: 10179796
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: January 15, 2019
    Assignee: Rafael Pharmaceuticals, Inc.
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Patent number: 10058100
    Abstract: The invention relates to a compound comprising a mitochondrial targeting group linked to group capable of releasing hydrogen sulfide, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body by surgery or therapy. The invention also relates to the use of the compound in the treatment of a plant, and to certain forms of the compound.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: August 28, 2018
    Assignee: The University of Exeter
    Inventors: Mark Wood, Matthew Whiteman, Alexis Perry
  • Patent number: 9872845
    Abstract: The invention provides a method of treating myeloma and lymphoma using a pharmaceutical composition containing a pharmaceutically acceptable diluent along with an ion pair formed by triethanolamine and a compound of Formula I:
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: January 23, 2018
    Assignee: Rafael Pharmaceuticals, Inc.
    Inventors: Robert G. L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
  • Patent number: 9572810
    Abstract: The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: February 21, 2017
    Assignee: REVEN PHARMACEUTICALS, INC.
    Inventors: Peter Lange, Brian Denomme, Henk Van Wyk, Mariette Van Wyk, Tracy L. Krebs, Sezgin Ozgur, Zishan Haroon
  • Patent number: 9492431
    Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: November 15, 2016
    Assignee: YAMAGUCHI UNIVERSITY
    Inventor: Kazuhiro Kimura
  • Patent number: 9345791
    Abstract: The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogs, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: May 24, 2016
    Assignee: Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Guenter Haufe, Bodo Levkau, Michael Schaefers, Stefani Silke Schilson, Petra Keul
  • Patent number: 9265741
    Abstract: This invention is of particular use to patients with Diabetes Mellitus. It uses alkyl analogs of the methyl pyruvate (MP) family to provide energy and improve insulin and glucose homeostasis via accelerated intracellular delivery of protons, pyruvate and ATP from each MP. The energy upregulates cellular cross talk and networking resulting in a surge of ATP enabling NADH (via glycolysis) that enables pancreatic islet cells to obtain increased ATP allowing increased insulin manufacture. This process improves cellular respiration, expedites protein, lipid and hormone manufacture. The increased energy also enables telomeres and delays Hayflick limit. Instead of cellular repair, silence, or apoptosis, energy is allocated for cell/organ function. This invention curbs inflammation and ROS by idealizing cellular respiration and diminishing hyperglycemia. In turn a reduction of advanced glycation end products (AGEs), lessened target RNA and nucleic acid toxins, i.e., diminished HbA1c occurs.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 23, 2016
    Assignee: Neville Pharmaceutical, INC.
    Inventor: Donald P Orofino
  • Patent number: 9233161
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.
    Type: Grant
    Filed: February 10, 2013
    Date of Patent: January 12, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9205112
    Abstract: Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: December 8, 2015
    Assignee: Creative Medical Health, Inc.
    Inventors: Neil Riordan, Fabio Salazar, Thomas E. Ichim
  • Patent number: 9192560
    Abstract: A cosmetic composition including diacetylresveratryl thioctate and a solvent. The solvent has a h value less than or equal to 8 and a d value greater than or equal to 16.9. Also, the use of the abovementioned composition to prevent and/or combat skin ageing.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: November 24, 2015
    Assignee: CHANEL PARFUMS BEAUTE
    Inventor: Odile Fournier
  • Patent number: 9173917
    Abstract: The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: November 3, 2015
    Assignees: Max International, LLC, The United States of America as represented by the Department of Veteran Affairs
    Inventors: Herbert T. Nagasawa, Jonathan F. Cohen
  • Patent number: 9040576
    Abstract: A nutritional supplement is provided comprising alpha-lipoic acid and curcumin. The nutritional supplement may be used for reducing weight or reducing weight gain, for reducing fat or reducing fat gain, for reducing loss in lean mass or maintaining lean mass, or for reducing loss of appetite or for maintaining appetite.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: May 26, 2015
    Assignee: Northern Innovations Holding Corp
    Inventors: Debasis Bagchi, John Doherty, Philip Apong, Vaishali Joshi, Jason Peters
  • Patent number: 9040082
    Abstract: Pharmaceutical compositions and methods for the treatment of chronic fatigue in human patients comprising a central nervous system (CNS) stimulant in a daily low-dosage amount in combination with therapeutically effective daily amounts of micronutrients, comprising acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS and micronutrient components may be in an oral dosage composition containing a low dosage amount of CNS stimulant such as about 2.5 mg methylphenidate HCl together with about 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cysteine, and 25-100 mg alpha-lipoic acid.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: May 26, 2015
    Inventor: Jon D. Kaiser
  • Publication number: 20150141500
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depressive disorders, anxiety disorders, attention deficit hyperactivity disorder, migraine prophylaxis, eating disorders, bipolar disorder, post-herpetic neuralgia, insomnia, ankylosing spondylitis, recurring biliary dyskinesia, nocturnal enuresis, cyclic vomiting syndrome, post-traumatic stress disorder (PTSD) and neuropathy.
    Type: Application
    Filed: February 17, 2013
    Publication date: May 21, 2015
    Inventor: Mahesh KANDULA
  • Publication number: 20150141384
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological degenerative disorders, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Alzheimer's disease, Lewy body disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
    Type: Application
    Filed: June 23, 2013
    Publication date: May 21, 2015
    Inventor: Mahesh KANDULA
  • Publication number: 20150133533
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing cough may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute respiratory tract infections, asthma, gout, fibromyalgia, facilitating conception, promotes secondary mucosal secretions in the respiratory system, muscle relaxant, allergy, asthma, chronic obstructive pulmonary disorders, spasms, respiratory and neurological diseases.
    Type: Application
    Filed: January 30, 2013
    Publication date: May 14, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150133407
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 14, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150133408
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.
    Type: Application
    Filed: February 16, 2013
    Publication date: May 14, 2015
    Inventor: Mahesh KANDULA
  • Publication number: 20150126591
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used for the treatment of Huntington's disease, Alzheimer's disease, Multiple Sclerosis, Lateral Sclerosis, Neural Motor disorders.
    Type: Application
    Filed: March 21, 2013
    Publication date: May 7, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150126592
    Abstract: The invention encompasses pet food compositions and methods for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or prevention of degenerative joint conditions, osteoarthritis, cartilage damage, and maintaining or increasing bone mineral density, wherein the compositions and methods include feeding a companion animal a composition including lipoic acid or a salt thereof.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 7, 2015
    Inventor: Nolan Zebulon Frantz
  • Publication number: 20150119452
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.
    Type: Application
    Filed: February 10, 2013
    Publication date: April 30, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150119453
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder (MDD), anxiety, neurological diseases, general anxiety disorder, social phobia, panic disorder, vasomotor symptoms, diabetic neuropathy, epilepsy, bipolar disorder, migraine, schizophrenia, cancer, menopause, HIV and familial adenomatous polyposis.
    Type: Application
    Filed: February 1, 2013
    Publication date: April 30, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150119423
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of local pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of moderate to severe pain, neuropathic pain, post herpetic neuralgia and rheumatic pains.
    Type: Application
    Filed: May 18, 2013
    Publication date: April 30, 2015
    Inventor: Mahesh Kandula
  • Patent number: 9018245
    Abstract: The purpose of the present invention is to elucidate a relationship between deregulation of signaling by CD22 and a rapid response of B cells by IgG-BCR and the like, and to provide a method capable of inducing a rapid immune response and defending against infection instead of vaccine. The present invention relates to a method for promoting an immune response causing such a strong proliferation of clones and production of a large amount of antibody-producing cells as those seen in the memory immune response even in the naive B cells expressing IgM-BCR and IgD-BCR by inhibiting the CD22 function in B cells; and to a method for screening a substance capable of promoting the immune response based on a change in the CD22 function in B cells.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: April 28, 2015
    Assignee: Japan Science and Technology
    Inventors: Takeshi Tsubata, Taishi Onodera
  • Publication number: 20150111959
    Abstract: Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.
    Type: Application
    Filed: October 28, 2014
    Publication date: April 23, 2015
    Inventors: William GARNER, Margaret Garner, George Minno, David Gooden
  • Patent number: 9012492
    Abstract: The present application relates to novel apocynin-lipoic acid covalent conjugates, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions that are mediated by oxidative stress. In particular, the present application includes compounds of Formula (I), and compositions and uses thereof.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: April 21, 2015
    Assignee: University of Prince Edward Island
    Inventors: Tarek Saleh, Desikan Rajagopal, Bobby Khan, Barry James Connell
  • Publication number: 20150093454
    Abstract: The present invention relates to a composition comprising alfa-lipoic acid, or a salt or complex thereof, and honokiol, wherein the weight quantity of said honokiol is between 1% and 30% with respect to the total weight of honokiol and alfa-lipoic acid.
    Type: Application
    Filed: April 19, 2013
    Publication date: April 2, 2015
    Inventors: Carlo Terruzzi, Fabio Terruzzi
  • Publication number: 20150087697
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing muscle pain, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, muscle pain, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications.
    Type: Application
    Filed: January 25, 2013
    Publication date: March 26, 2015
    Inventor: Mahesh KANDULA
  • Publication number: 20150080345
    Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
    Type: Application
    Filed: February 28, 2013
    Publication date: March 19, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150065564
    Abstract: The present invention relates, in various embodiments, to a compound represented by Structural Formula (I), pharmaceutically acceptable salts or prodrugs thereof, and compositions comprising said compounds, or pharmaceutically acceptable salts or prodrugs thereof. Methods of using compounds of Structural Formulas (I) and (Ia) or compositions comprising compounds of Structural Formulas (I) and (Ia), or pharmaceutically acceptable salts or prodrugs thereof, to treat ischemia or ischemia-reperfusion injury are also disclosed.
    Type: Application
    Filed: August 11, 2014
    Publication date: March 5, 2015
    Inventors: Alexander B. Baguisi, Reinier Beeuwkes, Ralph Casale, Steven A. Kates, Alan S. Lader
  • Patent number: 8969354
    Abstract: The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: March 3, 2015
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Publication number: 20150045393
    Abstract: The invention provides for novel cysteine protease inhibitors and compositions comprising novel cysteine protease derivatives. The invention further provides for methods for treatment of neurodegenerative diseases comprising administration novel cysteine protease inhibitors or compositions comprising novel cysteine protease inhibitors. In some embodiments, the cysteine protease inhibitors are calpain inhibitors.
    Type: Application
    Filed: February 1, 2013
    Publication date: February 12, 2015
    Inventors: Greg R. Thatcher, Isaac Thomas Schiefer, Ottavio Arancio, Mauro Fa
  • Patent number: 8952052
    Abstract: The invention encompasses pet food compositions and uses thereof for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or prevention of degenerative joint conditions, osteoarthritis, cartilage damage, and maintaining or increasing bone mineral density, wherein the compositions and uses include feeding a companion animal a composition including uses acid or a salt thereof.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: February 10, 2015
    Assignee: Hill's Pet Nutrition, Inc.
    Inventor: Nolan Zebulon Frantz
  • Publication number: 20150038563
    Abstract: A cosmetic composition including diacetylresveratryl thioctate and a solvent. The solvent has a h value less than or equal to 8 and a d value greater than or equal to 16.9. Also, the use of the abovementioned composition to prevent and/or combat skin ageing.
    Type: Application
    Filed: April 10, 2013
    Publication date: February 5, 2015
    Applicant: CHANEL PARFUMS BEAUTE
    Inventor: Odile Fournier
  • Patent number: 8946451
    Abstract: The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: February 3, 2015
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Publication number: 20150023923
    Abstract: The present disclosure relates to methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising docosahexaenoic acid and alpha-lipoic acid. The nutritional composition may further include lactoferrin, a prebiotic, a probiotic, and mixtures thereof. Additionally the present disclosure provides methods for accelerating the development of neuronal activity and/or strengthening electrochemical synapse signaling by providing the nutritional composition(s) disclosed herein to a target subject.
    Type: Application
    Filed: July 16, 2013
    Publication date: January 22, 2015
    Inventors: Chenzhong Kuang, Yan Xiao, Eduard Poels, Zeina Jouni, Dirk Hondmann
  • Publication number: 20140378522
    Abstract: The present invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering N-Acetylcysteine (NAC), melatonin, or a combination thereof. The present invention also relates to methods for diagnosing cancer and/or neurdegenerative disease by detecting or determining the amount of dopamine metabolites, 4-CE, 2-CE, methylation of CE or CE-Q conjugates.
    Type: Application
    Filed: January 13, 2014
    Publication date: December 25, 2014
    Applicant: Prevention, L.L.C.
    Inventors: Ercole L. Cavalieri, Eleanor G. Rogan
  • Publication number: 20140363523
    Abstract: The present invention provides a compound of Formula (I), wherein: each X is independently hydrogen or deuterium; and at least one X is deuterium.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 11, 2014
    Inventor: Adam Morgan
  • Publication number: 20140357680
    Abstract: The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
    Type: Application
    Filed: April 4, 2014
    Publication date: December 4, 2014
    Inventor: Mahesh Kandula
  • Publication number: 20140357691
    Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.
    Type: Application
    Filed: June 12, 2014
    Publication date: December 4, 2014
    Inventors: William GARNER, Margaret GARNER, George MINNO, David GOODEN
  • Publication number: 20140315989
    Abstract: The present application relates to novel apocynin-lipoic acid covalent conjugates, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions that are mediated by oxidative stress. In particular, the present application includes compounds of Formula (I), and compositions and uses thereof.
    Type: Application
    Filed: November 15, 2012
    Publication date: October 23, 2014
    Inventors: Tarek Saleh, Desikan Rajagopal, Bobby Khan, Barry James Connell
  • Publication number: 20140309293
    Abstract: The invention concerns a new polymorphic form of R-(+)-?-lipoic acid and a process for the preparation thereof, in addition to the compositions that contain it and its use as a medicine or food supplement.
    Type: Application
    Filed: July 6, 2012
    Publication date: October 16, 2014
    Applicant: LABORATORIO CHIMICO INTERNAZIONALE S.P. A.
    Inventors: Antonio Nardi, Annibale Salvi, Flavio Villani, Bruno De Angelis, Giorgio Bertolini
  • Publication number: 20140301998
    Abstract: Disclosed is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a concentration of from 0.1 to 25% by weight, based on the total weight of the formulation.
    Type: Application
    Filed: June 2, 2014
    Publication date: October 9, 2014
    Applicant: BEIERSDORF AG
    Inventors: Rainer KROPKE, Jens NIELSEN, Kathrin WOLTER
  • Patent number: 8853259
    Abstract: The invention provides mutual ternary salts of metformin, lipoic acid and acidic amino acids such as aspartic acid and glutamic acid. The invention further provides treatment of prediabetes, diabetes, diabetic complications and/or other conditions in mammals in a method that comprises administering an effective amount of one or more of the foregoing compositions to a mammal in need of such treatment.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: October 7, 2014
    Inventor: Banavara L. Mylari
  • Publication number: 20140286922
    Abstract: A method of measuring the effect of an active agent or a stressor on the baseline metabolic indicators of one or more hair follicles, the method including (a) obtaining one or more hair follicles; (b) placing the one or more hair follicles in a vessel, wherein the one or more hair follicles are positioned under one or more sensors; (c) using the one or more sensors to measure the one or more hair follicles' baseline metabolic indicators for both glycolysis and oxidative phosphorylation; (d) exposing the one or more hair follicles to an active agent or a stressor; and (e) using the one or more sensors to measure the one or more hair follicles' respondent metabolic indicators for both glycolysis and oxidative phosphorylation.
    Type: Application
    Filed: March 19, 2014
    Publication date: September 25, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Ben Charlton HULETTE, Thomas Larry DAWSON, JR.
  • Patent number: 8840883
    Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. Addition of a non-protein-type metal chelator provided further improvement in the action of the bio-functional activity of T3. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: September 23, 2014
    Assignee: Naidu LP
    Inventors: A. Satyanarayan Naidu, A. G. Sreus Naidu, A. G. Tezus Naidu
  • Publication number: 20140271879
    Abstract: Fine dry particulate retinoid compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate retinoid compositions, the retinoid active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate retinoid compositions of the invention, and methods of using the same.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Zahra Mansouri, Xin Chen, Rodica-Tatiana Canelide
  • Publication number: 20140248249
    Abstract: A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and one or more of a natural molecule or fragment thereof in at least one carrier to a patient in need of treatment, wherein the natural molecule is non-acetylated, non-Esterified, and non-fatty acid attached.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Inventors: Nayan Patel, Chinh Tran
  • Publication number: 20140243400
    Abstract: The invention relates to compositions comprising at least about 500 mg of citric acid; at least about 500 mg of malic acid; and at least about 100 mg of N-acetylcysteine, or at least about 100 mg of ?-lipoic acid, or a mixture thereof and methods for use of the compositions thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: February 27, 2014
    Publication date: August 28, 2014
    Inventor: Colin McGill
  • Patent number: 8815937
    Abstract: The present invention relates, in various embodiments, to a compound represented by Structural Formula (I), pharmaceutically acceptable salts or prodrugs thereof, and compositions comprising said compounds, or pharmaceutically acceptable salts or prodrugs thereof. Methods of using compounds of Structural Formulas (I) and (la) or compositions comprising compounds of Structural Formulas (I) and (la), or pharmaceutically acceptable salts or prodrugs thereof, to treat ischemia or ischemia-reperfusion injury are also disclosed.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: August 26, 2014
    Assignee: Ischemix LLC
    Inventors: Alexander B. Baguisi, Reinier Beeuwkes, Ralph Casale, Steven A. Kates, Alan S. Lader